Navigation Links
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Date:10/28/2011

INDIANAPOLIS, Oct. 28, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted approval for the use of ALIMTA® (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer (NSCLC). The approval is based on clinical trial results showing an improvement in progression-free survival, as well as a preliminary analysis showing a strong trend toward better overall survival, for NSCLC patients treated first with ALIMTA plus cisplatin and then continue treatment with ALIMTA alone in the maintenance setting.

ALIMTA is the first chemotherapy agent to be approved in Europe for continuation maintenance therapy. In this setting, patients whose disease has not progressed immediately following first-line treatment with ALIMTA plus cisplatin can continue maintenance treatment with ALIMTA alone and achieve additional benefit.

Continuation maintenance therapy with ALIMTA is specifically tailored to benefit the group of patients with a particular type of NSCLC, called nonsquamous, and who have shown a positive response or disease stabilization after treatment with first-line ALIMTA plus cisplatin. Although other maintenance regimens are currently available for NSCLC, they involve using different medicines in the maintenance phase of treatment than were used in the first-line setting.

"This latest approval for ALIMTA represents an important advance in the treatment of advanced lung cancer," said Allen Melemed, M.D., M.B.A., senior medical director with Lilly Oncology. "Tailored therapies have come to the forefront of cancer treatment because they allow clinicians to select the right treatment for the right patient. With ALIMTA continuation maintenance therapy, patients with lung cancer who have a
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
2. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
3. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
4. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
5. ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
6. ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   Fruit Street Health (Fruit Street), today ... of funding. The round, which includes ... of individual investors, the majority of whom are prominent ... round are; Houston Cardiology Consultants Partner Asif Ali, ... Rapha Family Medicine Practice Owner Frances Ilozue , ...
(Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 CarePoint Health ... removal of a cancerous prostate, along with the adjacent ... new da Vinci robotic Xi platform was performed at ... performed by Dr. Mutahar Ahmed and Dr. Yale Shulman ... and anesthesiologists, specifically trained for robotic procedures. The robot ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
(Date:9/18/2014)... New research led by Queen,s University professor Robert Campbell ... surgery is not helpful or necessary., Glaucoma is the ... and about 400,000 Canadians are afflicted with the disease, ... being high enough to damage the optic nerve. The ... eye to the brain and is a vital part ...
(Date:9/18/2014)... German . In ... fight a pathogen tooth and nail, but rather tolerate it to ... of tolerance is that the disease only progresses very slowly ... pathogen load. , Roland Regoes, a senior scientist at ETH Zurich,s ... He set about investigating whether there are infected people who are ...
(Date:9/18/2014)... September 18, 2014 It is almost time ... or walk for healthier and happier kids. The South ... in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place on ... be outside of Coral Gables City Hall located at 405 ...
Breaking Medicine News(10 mins):Health News:CarePoint Health Physicians Perform the First Prostatectomy in New Jersey Using the da Vinci Xi Robot 2Health News:CarePoint Health Physicians Perform the First Prostatectomy in New Jersey Using the da Vinci Xi Robot 3Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3
... get the blues during the course of the winter and ... far more difficult to overcome the seasonal affective disorder (SAD), ... ,Those who suffer from SAD overeat, sleep ... irritability and depression and develop an aversion to social interactions. ...
... associated with several alleged miscarriages of justice has been ... decision has been hailed as one to preserve public ... officials in Saskatchewan have voted to curtail practicing privileges ... Smith. ,Smith had been granted temporary ...
... are reporting that the traditional method of assessing the ... the danger //of missing one-third of women who are ... ,Roger Blumenthal, M.D., an associate professor and ... Johns Hopkins University School of Medicine and its Heart ...
... University of Chicago have announced findings of archeological evidence that ... leading to the destruction of a city. Clemens Reichel, a ... was conducted was a war zone. Artifacts from daily life ... at the Iraqi border. ,The findings prove ...
... milk is so there is study in Australia ... with nutraceutical, pharmaceutical and agrochemical potential.// ... Queensland's Institute for Molecular Bioscience (IMB) and the ... has teamed up with MG Nutritionals for the ...
... Woo Suk the cloning pioneer of South Korea is defending ... editors of Science magazine in Washington to retract his work.//, ... magazine, Donald Kennedy said that Hwang would have 'days or ... his bid to retract a pioneering article that held out ...
Cached Medicine News:Health News:Calcium Levels Could Indicate Future Heart Disease Risk 2Health News:Excavations Reveal Clues Of Early Warfare 2Health News:Scientist Calls Upon Media To Retract His Work 2
10 L, Racked, 96 tips/rack Extended length pipette tips recommended for 5 and 10 L pipettes....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 ul reference mark make it ideal for low volume pipetting....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
... Diagnostics West Nile Virus IgG DxSelect ... to West Nile virus in human,serum. ... West Nile Virus,IgM Capture DxSelect, the ... symptoms of meningioencephalitis, as an aid ...
Medicine Products: